

14 February 2022



The Nifty previous session ended 3.06% down at 16842.80. It opened gap-down and continued declining steadily towards finishing off along the most critical pivotal trend line support placed around 16800 levels. Pull back is likely from around 16800 levels, however, breaking out 17100 also looks difficult. Lower support below 16800 is placed around 16700 levels. Nifty initial trading range likely to be 16800-17100.

On the Nifty hourly chart, oversold RSI suggesting a pullback from around the Nifty 16800 levels. Intraday trading range likely to be 16800-17100.

Nifty patterns on multiple periods suggest; coming down onto the most critical misterm trend line support placed around 16800 gives another buying opportunity. Oversold sector leaders might be helpful in taking the Benchmark Index towards 17100 levels.

Nifty Crucial Supports & Resistances-

Supports- 16800, 16700 Resistances- 16950, 17100

Key Contents	Page No.
Result Update	4
Domestic News	6

Open Positional Calls-

T+10 INST POSITIONAL BUY-
|Cash Segment| BRITANNIA @ 3460-3450, TGT- 3650, Closing SL- below 3350

T+14 INST POSITIONAL BUY-
|Cash Segment| BATA @ 1900-1880, TGT- 2040, Closing SL- below 1800

T+7 BUY-
|Cash Segment| RIL @ 2330-2310, TGT - 2420, Closing SL- below 2260

T+10 INST POSITIONAL BUY-
|Cash Segment| M&M @ 840-830, TGT- 890, Closing SL- below 800

T+7 BUY-
|Cash Segment| CRISIL @ 2750-2740, TGT- 2840, Closing SL- below 2690

T+7 INST POSITIONAL BUY-
|Cash Segment| INDUSIND BANK @ 945-940, TGT- 990, Closing SL- below 915

Nifty Intraday Chart



Market in Retrospect

India's stock benchmarks logged the worst day in ten months since April 12, 2021, amid decline in global equities, rise in oil prices, escalating geopolitical tensions and inflation pressures.

Nifty index ended 3.06% lower at 16,843. The broader markets represented by the Nifty 500 Index ended 3.30% lower, ending at 14,400. Among the sectorial indices all indices ended lower among them Nifty Metal was the top loser losing by 5.06%.

TCS was the only gainer, gaining by 1.05%. JSW Steel was the top loser, losing by 6.68%, followed by HDFC Life Insurance and Tata Motors which fell by 6.39% & 5.49% respectively.

The Advance : Decline ratio stood at 267:1911.

Market Turnover (In Crore) 14-02-2022

Name	Last	Previous
NSE Cash	62399.60	59777.87
NSE F&O	6851942.08	5438143.46
BSE Cash	5,230.84	4,892.69
BSE F&O	114.41	81.75

FII Derivatives Flow (In Crore) 11-02-2022*

Instrument	Purchase	Sale	Net
Index Future	4327.46	5380.24	1052.78
Index Option	458666.62	456787.18	1879.44
Stock Future	14113.65	15127.48	1013.83
Stock Option	13808.67	14053.39	244.72

Institutional Flow (In Crore) 11-02-2022*

Institution	Purchase	Sale	Net
FII	9754.86	9646.33	108.53
DII	5537.23	6234.13	696.9

NIFTY Top Gainers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
TCS	1.05	1.20	5951745	2493652

NIFTY Top Losers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
HDFC	5.34	5.41	5903697	5468404
Tata Steel	5.39	0.33	8021613	11002970
Tata Motors	5.49	4.68	22157389	15455020
HDFC Life Insurance	6.39	7.62	7168038	3283838
JSW Steel	6.68	3.78	6491576	3112149

Bulk and Block Deals

<https://www.nseindia.com/products/content/equities/equities/bulk.htm>
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.aspx>

*data not updated till 6:30PM

Sensex Intraday Chart



Market in Detailed (Updated after 4:00 PM)

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	56405.84	1747.08	3.00	2.11	7.87	7.10	8.15
Nifty	16842.80	531.95	3.06	2.15	7.74	6.99	9.98
BSE M Cap	23398.52	852.40	3.51	4.27	10.30	11.26	17.52
BSE S Cap	27501.30	1190.52	4.15	6.71	11.15	5.92	40.16
Nifty MC 100	28558.75	1170.65	3.94	5.21	10.73	10.55	24.63
BSE Auto	25184.37	933.20	3.57	2.26	4.22	4.36	2.22
BSE Capgoods	27535.43	1016.16	3.56	5.19	10.82	5.39	26.34
BSE FMCG	13107.69	398.66	2.95	3.54	5.92	8.09	4.80
BSE Metal	20005.32	68.78	0.33	3.69	3.56	4.00	67.98
BSE Oil&Gas	17785.07	444.99	2.44	3.00	5.77	6.83	20.12
BSE Healthcare	23853.40	508.95	2.09	1.95	7.43	5.19	9.54
BSE Power	3757.84	140.52	3.60	5.61	2.32	5.75	66.91
BSE Realty	3474.12	190.84	5.21	6.46	14.04	19.41	24.40
BSE ConsDur	41059.93	1143.37	2.71	3.13	10.42	9.34	25.55
BSE Bank	42215.83	1872.42	4.25	3.09	3.55	4.56	3.38
BSE IT	33652.96	618.29	1.80	2.61	12.46	4.80	29.57

Bond Markets

Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	1.95	0.02	0.81	1.92	9.45	25.07	61.62
UK	1.52	0.03	1.94	7.60	31.74	65.76	193.04
Brazil	5.08	0.06	1.22	2.92	4.59	10.15	48.28
Japan	0.22	0.01	5.63	10.66	52.45	186.84	220.59
Australia	2.14	0.07	3.26	7.17	15.51	19.11	75.10
India	6.67	0.03	0.48	2.04	1.28	4.68	11.29
Switzerland	0.29	0.04	13.33	3.05	959.26	301.41	189.66
Germany	0.24	0.06	20.88	3.07	610.87	190.73	154.91

Currency

Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	75.60	0.22	0.30	1.20	1.91	1.48	3.85
USD Index	96.30	0.22	0.23	0.95	1.19	1.23	6.43
YUAN	6.36	0.00	0.06	0.06	0.09	0.39	1.57
GBP	1.35	0.00	0.19	0.01	1.00	0.91	2.63
EUR	1.13	0.00	0.13	0.94	0.67	0.29	6.55
YEN	115.37	0.05	0.04	0.23	1.02	1.08	8.66

Freight

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	1977.00	37.00	1.91	39.03	12.07	29.57	47.65
Baltic Dirty	687.00	6.00	0.88	0.73	1.58	16.32	27.46
SG Dubai HY	6.82	0.00	0.00	5.08	9.65	86.85	1055.93

Global Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	34738.06	503.53	1.43	1.00	3.27	3.77	10.43
Nasdaq	13791.15	394.49	2.78	2.18	7.40	13.05	2.16
S&P 500	4418.64	85.44	1.90	1.82	5.24	5.64	12.30
FTSE100	7509.44	151.39	1.98	0.84	0.44	2.20	13.96
CAC40	6775.54	234.30	3.34	3.31	5.12	4.43	18.82
DAX	14929.78	490.78	3.18	1.79	5.97	7.21	6.30
Mexico IPC	53229.27	629.69	1.20	4.07	0.96	3.49	20.42
Brazil Bovespa	113572.4	204.60	0.18	1.18	6.21	6.81	4.90
Russian RTS	1436.53	36.49	2.48	0.80	3.52	19.65	1.94
Japan Nikkei	27079.59	616.49	2.23	1.31	3.71	9.06	9.99
Hang Seng	24556.57	350.09	1.41	0.09	0.71	3.29	18.62
Taiwan Index	17997.67	313.27	1.71	0.54	2.20	2.06	13.89
Shanghai Comp	3428.88	34.07	0.98	0.02	2.62	2.96	6.19
KOSPI	2704.48	43.23	1.57	1.48	7.44	9.84	14.06
Malaysia KLCI	1583.84	4.95	0.31	3.47	1.83	4.04	1.51
Jakarta Comp	6734.48	81.12	1.19	1.04	0.61	1.79	7.40
Philippine SE	7361.15	90.79	1.25	0.26	1.37	0.26	5.78
Thai Exch	1684.69	14.51	0.85	0.44	0.72	2.80	10.64

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	92.61	0.44	0.47	1.47	10.55	14.69	55.81
BRENT Crude	93.94	0.48	0.51	1.37	10.09	18.38	64.41
Natural Gas	4.13	0.18	4.67	2.53	1.08	8.92	37.32

LME

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1853.44	4.88	0.26	1.84	1.98	0.59	1.63
Silver(\$/Ounce)	23.68	0.11	0.46	2.96	3.18	6.42	13.40
Aluminium	3146.50	120.50	3.69	1.55	6.33	18.41	51.53
Copper	9894.25	410.75	3.99	0.24	1.64	0.85	19.36
Zinc	3621.00	85.75	2.31	0.11	1.25	9.96	30.66
Lead	2286.55	4.10	0.18	4.36	1.27	4.59	9.24

Agro Commodities

Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	252.80	0.75	0.30	4.33	5.53	13.64	92.39
Cotton	122.51	0.40	0.33	0.40	5.30	8.08	47.89
Sugar	17.84	0.03	0.17	0.79	1.33	9.81	23.72
Wheat	806.75	2.75	0.34	3.96	8.36	3.06	27.05
Soybean	1566.50	19.75	1.25	1.25	13.56	23.79	38.41

Gateway Distriparks

Net profit of Gateway Distriparks rose 43.97% to Rs 48.07 crore in the quarter ended December 2021 as against Rs 33.39 crore during the previous quarter ended December 2020. Sales rose 11.31% to Rs 349.28 crore in the quarter ended December 2021 as against Rs 313.80 crore during the previous quarter ended December 2020.

Grasim Industries

Net profit of Grasim Industries rose 45.99% to Rs 522.47 crore in the quarter ended December 2021 as against Rs 357.87 crore during the previous quarter ended December 2020. Sales rose 56.49% to Rs 5784.74 crore in the quarter ended December 2021 as against Rs 3696.61 crore during the previous quarter ended December 2020.

Hikal

Net profit of Hikal rose 12.21% to Rs 45.20 crore in the quarter ended December 2021 as against Rs 40.28 crore during the previous quarter ended December 2020. Sales rose 9.66% to Rs 506.62 crore in the quarter ended December 2021 as against Rs 462.01 crore during the previous quarter ended December 2020.

Ipca Laboratories

Net profit of Ipca Laboratories declined 26.04% to Rs 196.33 crore in the quarter ended December 2021 as against Rs 265.47 crore during the previous quarter ended December 2020. Sales rose 1.46% to Rs 1430.47 crore in the quarter ended December 2021 as against Rs 1409.83 crore during the previous quarter ended December 2020.

KNR Constructions

Net profit of KNR Constructions declined 48.94% to Rs 49.81 crore in the quarter ended December 2021 as against Rs 97.55 crore during the previous quarter ended December 2020. Sales rose 16.32% to Rs 854.64 crore in the quarter ended December 2021 as against Rs 734.71 crore during the previous quarter ended December 2020.

Manappuram Finance

Net profit of Manappuram Finance declined 45.88% to Rs 261.00 crore in the quarter ended December 2021 as against Rs 482.24 crore during the previous quarter ended December 2020. Sales declined 9.69% to Rs 1484.45 crore in the quarter ended December 2021 as against Rs 1643.81 crore during the previous quarter ended December 2020.

Bharat Dynamics

Bharat Dynamics reported net profit surged 333.54% to Rs 213.26 crore on 75.13% increase in total revenue from operations sales to Rs 803.90 crore in Q3 December 2021 over Q3 December 2020. Profit before tax (PBT) rose 335.57% to Rs 298.54 crore in Q3 December 2021 over Q3 December 2020. Total expenses rose 26.96% year-on-year to Rs 540.02 crore in Q3 December 2021. Cost of raw material consumed increased 27.46% to Rs 316.59 crore. The firm's board declared an interim dividend Rs 7.30 per share for the Financial Year 2021-22.

Varroc Engineering

Net Loss of Varroc Engineering reported to Rs 265.16 crore in the quarter ended December 2021 as against net loss of Rs 138.73 crore during the previous quarter ended December 2020. Sales declined 10.24% to Rs 3134.95 crore in the quarter ended December 2021 as against Rs 3492.66 crore during the previous quarter ended December 2020.

VST Tillers Tractors

Net profit of VST Tillers Tractors declined 31.72% to Rs 21.05 crore in the quarter ended December 2021 as against Rs 30.83 crore during the previous quarter ended December 2020. Sales rose 2.75% to Rs 208.44 crore in the quarter ended December 2021 as against Rs 202.87 crore during the previous quarter ended December 2020.

Dabur becomes first Indian plastic waste neutral' FMCG company in India

Dabur India, India's largest Ayurveda company said it has become a complete plastic waste neutral firm in the country after collecting, processing and recycling around 27,000 metric tonnes of post-consumer plastic waste during FY21-22. With this, Dabur has become the first Indian consumer goods company to achieve the landmark of surpassing its plastic packaging usage with recycling.

BHEL bags order to supply compact heat exchanger sets for Tejas aircraft

Bharat Heavy Electricals Ltd (BHEL) on Monday said it has bagged an order from Hindustan Aeronautics Ltd to supply compact heat exchanger sets for Tejas aircraft. The order envisages manufacturing, assembly, testing and supply of compact heat exchangers to be fitted in the light combat aircraft, Tejas, being manufactured by HAL. The BHEL's Heavy Plates and Vessels Plant (HPVP), Visakhapatnam is the sole supplier of heat exchangers for LCA Tejas to HAL since 1996. The BHEL-HPVP and Aeronautical Development Agency (ADA), Bangalore have jointly designed and developed 13 different types of compact heat exchangers for Environmental Control System (ECS) and Secondary Power System (SPS) of LCA MK-1 programme. The BHEL is also currently working with DRDO for the development of Air Cycle Machine based Liquid Cooling System (LCS) for Aircraft POD application for LCA MK-2. The BHEL-HPVP has dedicated, intricate manufacturing and inspection facilities for manufacturing of state-of-the-art Compact Heat Exchangers for different types of aircraft manufactured by HAL.

Zydus Pharmaceuticals (USA) Inc gets final US FDA approval to market Roflumilast tablets

Cadlia Healthcare Ltd on Monday said group firm Zydus Pharmaceuticals (USA) Inc has received final approval from the US health regulator to market its generic version of Roflumilast tablets in the strength of 500 mcg indicated to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations. Zydus, being one of the first applicants for Roflumilast Tablets, 500 mcg, is eligible for 180 days of shared generic drug exclusivity. The US Food and Drug Administration (USFDA) has also given a tentative approval for Roflumilast tablets, 250 mcg. The group now has 327 approvals and has so far filed over 400 abbreviated new drug applications (ANDAs) since the commencement of the filing process in FY 2003-04.

CORPORATE ACTION BONUS / RIGHTS / STOCK SPLIT / DIVIDEND / FCCB / M&A / WARRANTS ETC.

Company	Details
Bhatia Communications & Retail India Ltd	10 for 1 stock split effective 15-02-22
Danube Industries Ltd	5 for 1 stock split effective 15-02-22
REC Ltd	Cash dividend of INR6 effective 15-02-22
AK Capital Services Ltd	Cash dividend of INR5 effective 15-02-22
IOL Chemicals and Pharmaceuticals Ltd	Cash dividend of INR4 effective 15-02-22
Dalmia Bharat Sugar & Industries Ltd	Cash dividend of INR3 effective 15-02-22
CE Info Systems Ltd	Cash dividend of INR2 effective 15-02-22
Suven Pharmaceuticals Ltd	Cash dividend of INR2 effective 15-02-22
Suven Pharmaceuticals Ltd	Cash dividend of INR1 effective 15-02-22
Aarti Industries Ltd	Cash dividend of INR1 effective 15-02-22
Minda Corp Ltd	Cash dividend of INR0.30 effective 15-02-22
Niyogin Fintech Ltd	Corporate meeting effective 15-02-22
Kilburn Engineering Ltd	Corporate meeting effective 15-02-22
Data Infrastructure Trust	Corporate meeting effective 15-02-22

Domestic Events

- No events

Global Events

- Japan Industrial Production for December 2021.
- The U.S. Balance of Trade for December 2021.
- Japan GDP Growth for Q4 2021.
- Euro Area Balance of Trade for December 2021.

Source of News : The content may have been taken from The Economic Times, Business Standard, Business Line, Mint and other leading financial newspapers and financial portals BSE,NSE, Bloomberg, Moneycontrol & others.

Analyst Certification:

We /I, Jaydeb Dey and Shreyansh N. Mehta Research Analyst(S) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document

to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report or at the time of Public Appearance.

SMIFS does not have proprietary trades but may at a future date, opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/short position in the above Scrip(s) and therefore should be considered as interested.

The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing, however the same shall have no bearing whatsoever on the specific recommendations made by the analysts, as the recommendations made by the analysts are completely independent views of the Associates of SMIFS even though there might exist an inherent conflict of interest in some of the stocks mentioned in the Research Report.

The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at www.nseindia.com and/or www.bseindia.com, www.mcxindia.com and/or www.icex.com.

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

Specific Disclosures

- SMIFS, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- SMIFS, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company.
- SMIFS, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months.
- SMIFS, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as director/officer/employee in the subject company
- SMIFS has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- SMIFS has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- SMIFS has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months.
- SMIFS has not received any compensation or other benefits from third party in connection with the research report.
- SMIFS has not engaged in market making activity for the subject company

Analyst holding in stock: **NO**

Key to SMIFS Investment Rankings

Buy: Return >15%, Accumulate: Return between 5% to 15%, Reduce: Return between -5% to +5%, Sell: Return < -5%

Contact us:

SMIFS Limited. (<https://www.smifs.com/>)

Compliance Officer:

Sudipto Datta,

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5401 /91 33 6634 5401

Email Id.: compliance@smifs.com
